What guidance did Haleon's management provide for the next earnings period?

What is the revenue and EPS growth rate for Haleon year over year?

What is Haleon's latest dividend and current dividend yield?

What were the key takeaways from Haleon’s earnings call?

What is Haleon's gross profit margin?

What factors drove the changes in Haleon's revenue and profit?

What were the key takeaways from Haleon's earnings call?

What does Haleon do and what are its main business segments?

- **2026 Growth Outlook**: 3-5% organic growth driven by U.S. recovery, emerging markets (India +10%, China e-commerce >100%), and $175-200M cost savings.
- **Strategic Reorganization**: Flattened structure with 6 operating units, AI-driven tools for faster execution, and new leadership in key markets.
- **A&P Efficiency**: +7.5% spend focused on Oral Health (Sensodyne +10%+), digital media (60%), and low-income consumer expansion, with mid-single-digit ROI improvement.
- **Supply Chain Excellence**: 220bps gross margin improvement from complexity reduction and operational efficiency, targeting 50-80bps annual gains.
- **Key Risks**: U.S. cold/flu season Q1 2026 expected below 2025, but 2026 phasing includes Q2 distribution gains and Oral Health resilience.

**【CEO Summary Section】**
- **2025 Performance**: Organic growth of 3%, below expectations due to U.S. market softness and cold/flu season challenges. 60% of business maintained or gained share despite market slowdown.
- **2026 Guidance**: 3-5% organic growth driven by U.S. recovery, emerging markets (India, China), and cost control. U.S. cold/flu season expected to be below 2025 levels in Q1 but improving through the year.
- **Reorganization**: Flattened structure with 6 operating units, $175-200M gross savings, and focus on AI-driven commercial execution. New leadership in U.S., India, and Latin America.
- **Medium-Term Ambition**: Confident in 4-6% growth through category leadership, innovation (e.g., 12-hour Voltaren patch), and low-income consumer expansion.

**【CFO Financial Commentary】**
- **Emerging Markets**: India (+10%+), China (e-commerce >100% growth), and Latin America outperformed. 80% of Asia Pac growth from volume, driven by rural expansion and low-income consumer strategies.
- **A&P Spending**: +7.5% in 2025, with half allocated to Oral Health (Sensodyne, Parodontax) and half to emerging markets. Digital media占比60%, ROI improved mid-single digits.
- **Supply Chain Efficiency**: 220bps gross margin improvement from complexity reduction (e.g., Aquafresh language packs down 60%) and operational debottlenecking.

**【Q&A Highlights】**
- **U.S. Market Dynamics**: Pharmacy channel shift to e-commerce (18 brands account for 90% of Amazon sales). 2026 focus on distribution gains (Q2 shelf resets), Advil share recovery, and Oral Health resilience.
- **A&P Effectiveness**: Oral Health ROI strong, with Sensodyne +10%+ globally. Pain Relief (Voltaren patch) and Digestive Health (Tums, Benefiber) seeing strategic initiatives despite Nexium headwinds.
- **Risk Management**: 2026 guidance accounts for uncertain market, with flexibility to reinvest savings into growth. Cold/flu season impact expected to ease post-2026.


Haleon plc (HLN) Q4 2025 Earnings Call Transcript

- **U.S. Challenges Persist**: North America underperforms with 2% Q2 decline, driven by smoking cessation trade-down and channel shifts. Smokers' Health innovation planned for 2026.
- **A&P Investment**: 6.8% A&P growth in H1, with 4% ROI improvement. Focus on low-income packs (e.g., India) and innovation (Nasal Mist).
- **Strategic Resilience**: 160bps gross margin expansion supports medium-term 4-6% growth, despite U.S. headwinds. Oral Health gains 0.5 share pts in U.S.
- **Brand Actions**: New Advil campaign shows green shoots; Centrum reactivates cognitive aging claims; Sensodyne e-commerce share 28% vs. 20% offline.

**【North America Performance】**
- Q2 organic sales declined 2%, underperforming the 4-6% medium-term guidance. Key challenges include:
  - Consumer trade-down in smoking cessation (e.g., Nicorette) due to $30-40 price point sensitivity.
  - Shift to value channels (Dollar/Club, e-commerce) with inventory pressures at retailers.
  - Mixed performance in Pain Relief (Advil share loss) and VMS (Centrum U.S. decline vs. strong global growth).
- Management expects gradual recovery, with share gains in Oral Health and initiatives like new Advil media campaigns.

**【A&P Spending】**
- A&P increased 6.8% in H1, driven by innovation (e.g., Nasal Mist, Dual Action Panadol) and strategic markets (India, EMEA).
- ROI improved 4%, with focus on low-income consumer packs (e.g., INR 20 Sensodyne in India).
- CFO expects similar A&P investment shape in H2, balancing growth and productivity.

**【U.S. Retailer Environment】**
- 25% of U.S. business via Walmart, with drug channel inventory management challenges.
- Smokers' Health (NRT) business down 60bps in Q2, with FDA-approved dual-layer tablet innovation planned for 2026.
- Despite channel shifts to e-commerce (Amazon growth), margin impact is neutralized by balanced omnichannel strategy.

**【Strategic Focus】**
- Maintaining medium-term 4-6% growth guidance, driven by:
  - Oral Health leadership (0.5 share pts gained in U.S. in H1).
  - Productivity initiatives (160bps gross margin expansion in H1).
  - Innovation-led premiumization (e.g., Centrum Silver cognitive aging claims).
- 60%+ share gain/maintain target achievable with U.S. stabilization, despite H1 58% result.


Haleon plc (HLN) Q2 2025 Q&A Earnings Call Transcript

- **Growth Drivers**: 4-6% FY25 revenue growth fueled by Oral Health innovation (Clinical White expansion) and emerging markets (India/China JV).
- **Risk Management**: 1% FX headwind offset by cost control; 13-day working capital improvement in FY24 with more gains possible.
- **Key Risks**: Elevated cold/flu inventory in Q1, slow Eroxon launch, and US retail sector stress.
- **Strategic Focus**: Capital allocation prioritizes growth (M&A) and returns (buybacks), with £500M buyback announced.


**【CEO Key Themes】**
- **2025 Growth Outlook**: 4-6% revenue growth driven by innovation, with Q1 softness due to elevated cold/flu inventory in mature markets. 71% of business gained/maintained share in FY24.
- **Emerging Markets Momentum**: India and China (via JV) leading growth. Oral Health division outperforming with Clinical White expansion to 12+ markets and new product launches.
- **Category Dynamics**: VMS category stabilizing post-COVID volatility. Emergency care brand shows seasonal variability tied to flu seasons.

**【CFO Financial Insights】**
- **Currency Impact**: 1% top-line/EPS headwind from FX, concentrated in H1. Long-term mitigation strategies include supply chain optimization and pricing.
- **Working Capital Efficiency**: 13-day improvement in FY24, with further gains possible via inventory management and receivables optimization.
- **Balance Sheet Management**: £500M buyback alongside retained flexibility for bolt-on M&A. Free cash flow remains key capital allocation priority.

**【Q&A Highlights】**
- **China JV Transition**: Full ownership enables operational synergies, though no material accounting changes. China business less impacted by inflation than Europe.
- **Eroxon Performance**: Slow launch for new OTC category, but within FY25 guidance. Innovation pipeline includes clinical platform extensions.
- **US Retail Challenges**: Select drug retailers facing cash constraints, but broader consumer demand remains stable.


Actual											0.2567
Forecast											0.2567
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Actual	--	--	--	--	--	--	--	--	--	--	7.52B	--
Forecast	--	--	--	--	--	--	--	--	--	--	7.52B	--
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+0.00%	0.00%

HLN

HLN fundamentals

HLN Q1 undefined Earnings

Earnings Call

You can ask Aime

HLN

HLN fundamentals

HLN Q1 undefined Earnings

Earnings Call

HLN Earnings Call Summary for Q1/2026Upcoming Apr 3, 2026

HLN Earnings Call Summary for Q4/20253:00 AM on Feb 25, 2026

HLN Earnings Call Summary for Q2/2025Invalid Date on Jul 31, 2025

HLN Earnings Call Summary for Q4/2024Invalid Date on Feb 27, 2025

HLN Earnings Call Summary for Q3/2024 Apr 3, 2026

You can ask Aime